ABBOTT LABORATORIES

Abbott Laboratories’ stock fell 15% in three years, yet Baird’s “Outperform” rating and $121 price target highlight its diverse portfolio and strong long‑term prospects.

Abbott Laboratories faces a $53 million lawsuit over preterm infant formula, analyst price‑target shifts, and active institutional trading—what it means for investors.

Abbott Laboratories’ $23 billion Exact Sciences deal unlocks a new oncology revenue stream, while its strong diabetes and nutrition businesses keep earnings steady—discover how the acquisition reshapes future growth.

Abbott’s $5.9 B Exact Sciences takeover boosts its cancer‑screening reach with Cologuard and Oncotype DX, fueling growth in a $60B U.S. diagnostics market.

Abbott Laboratories’ acquisition of Exact Sciences boosts its cancer‑diagnostics reach, adding Cologuard and Oncotype DX to drive high‑margin growth and early‑detection leadership.

Abbott Laboratories launches its XIENCE Skypoint cardiovascular platform in India, ending a 3‑year litigation saga and advancing digital diagnostics with ICRAS – a strategic shift toward high‑growth tech solutions and regulatory clarity.

Abbott Laboratories’ 2025 annual report and proxy reveal a focus on robust shareholder returns, independent board governance, and a global employee‑stock plan to drive future growth and sustainability in the healthcare sector.

Abbott Laboratories’ latest stock analysis reveals a $192B market cap, a P/E of 29.75, and a $109.56 NYSE price—insights on its health‑care innovation and investment risks.

Abbott Laboratories sees modest institutional selling amid strong fundamentals and market‑wide healthcare innovation, but remains a diversified, high‑cap leader.

Abbott’s free AI‑powered Libre Assist turns real‑time glucose data into instant meal guidance, boosting user engagement and positioning the company for growth in digital therapeutics.